Regnard J F, Magdeleinat P, Dromer C, Dulmet E, de Montpreville V, Levi J F, Levasseur P
Department of Thoracic and Vascular Surgery, Marie Lannelongue Hospital, Le Plessis-Robinson, France.
J Thorac Cardiovasc Surg. 1996 Aug;112(2):376-84. doi: 10.1016/S0022-5223(96)70265-9.
Three hundred seven cases of patients who underwent operation for thymoma (196 of whom had myasthenia gravis) were analyzed to assess the prognostic values of Masaoka clinical staging, completeness of resection, histologic classification, history of myasthenia gravis, and postoperative radiotherapy. According to the Masaoka staging system, 135 thymomas were stage I, 70 were stage II, 83 were stage III, and 19 were stage IV. According to the Verley and Hollmann histologic classification system, 67 thymomas were type 1, 77 were type 2, 139 were type 3, and 24 were type 4. Two hundred sixty patients underwent complete resection, 30 underwent incomplete resection, and 17 underwent biopsy. Postoperative radiotherapy was performed mainly in cases of invasive or metastatic thymoma. Mean follow-up was 8 years; eight patients were unavailable for follow-up. The overall 10- and 15-year survivals were 67% and 57%, respectively. In univariate analysis, three prognostic factors were established: completeness of resection, Masaoka clinical staging, and histologic classification. Furthermore, among patients with stage III thymomas, survival was significantly higher for patients with complete resection than for patients with incomplete resection (p < 0.001). Completeness of resection should therefore be taken into account in clinical-pathologic staging. We did not find any significant difference with respect to disease-free survival between patients who had postoperative radiotherapy and those who did not. In multivariate analysis, the sole significant prognostic factor was completeness of resection. On the basis of these findings, a new clinical-pathologic staging system is proposed.
对307例行胸腺瘤手术的患者(其中196例患有重症肌无力)进行分析,以评估Masaoka临床分期、切除完整性、组织学分类、重症肌无力病史及术后放疗的预后价值。根据Masaoka分期系统,135例胸腺瘤为Ⅰ期,70例为Ⅱ期,83例为Ⅲ期,19例为Ⅳ期。根据Verley和Hollmann组织学分类系统,67例胸腺瘤为1型,77例为2型,139例为3型,24例为4型。260例患者接受了完整切除,30例接受了不完全切除,17例接受了活检。术后放疗主要用于侵袭性或转移性胸腺瘤病例。平均随访8年;8例患者无法进行随访。总体10年和15年生存率分别为67%和57%。单因素分析确定了三个预后因素:切除完整性、Masaoka临床分期和组织学分类。此外,在Ⅲ期胸腺瘤患者中,完整切除患者的生存率显著高于不完全切除患者(p<0.001)。因此,在临床病理分期中应考虑切除的完整性。我们未发现术后放疗患者与未接受术后放疗患者在无病生存率方面有任何显著差异。多因素分析中,唯一显著的预后因素是切除完整性。基于这些发现,提出了一种新的临床病理分期系统。